Guilin Sanjin Pharmaceutical Co., Ltd. (SHE:002275)
China · Delayed Price · Currency is CNY 12.71
-0.27 (-2.08%)
Jun 11, 2026, 1:55 PM CST
SHE:002275 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,101 | 2,043 | 2,192 | 2,168 | 1,954 | 1,739 |
Other Revenue | 2.8 | 2.8 | 1.76 | 3.66 | 5.27 | 2.71 |
| 2,104 | 2,046 | 2,194 | 2,172 | 1,960 | 1,741 | |
Revenue Growth (YoY) | -3.38% | -6.76% | 1.03% | 10.81% | 12.55% | 11.15% |
Cost of Revenue | 497.95 | 508.56 | 610.47 | 602.57 | 574.37 | 457.04 |
Gross Profit | 1,606 | 1,537 | 1,584 | 1,569 | 1,385 | 1,284 |
Selling, General & Admin | 815.45 | 817.78 | 888.26 | 920.66 | 812.68 | 722.13 |
Research & Development | 174.93 | 160.04 | 173.29 | 158.06 | 217.04 | 201.6 |
Other Operating Expenses | 25.5 | 22.27 | 27.42 | 29.89 | 36.09 | 32.8 |
Operating Expenses | 1,073 | 1,023 | 1,098 | 1,109 | 1,070 | 957.81 |
Operating Income | 533.5 | 514.23 | 485.33 | 460.41 | 315.65 | 326.37 |
Interest Expense | -16.29 | -19.86 | -13.84 | -16.36 | -20.24 | -18.21 |
Interest & Investment Income | 22.18 | 23.87 | 34.4 | 33.17 | 40.64 | 39.8 |
Currency Exchange Gain (Loss) | 0.35 | 0.35 | 0.19 | -0.08 | -3.59 | 0.57 |
Other Non Operating Income (Expenses) | -0.15 | -0.22 | -0.25 | 0.05 | -0.58 | -1.23 |
EBT Excluding Unusual Items | 539.58 | 518.37 | 505.84 | 477.2 | 331.89 | 347.31 |
Gain (Loss) on Sale of Investments | 8.76 | 7.71 | 4.65 | 1.19 | 0.16 | 1.77 |
Gain (Loss) on Sale of Assets | 0.14 | 0.15 | 83.36 | 1.67 | 31.26 | 15.5 |
Asset Writedown | -0.73 | -0.73 | -0.86 | -0.17 | -1.02 | -8.12 |
Other Unusual Items | 11.51 | 11.42 | 50.95 | 38.39 | 83.89 | 72.61 |
Pretax Income | 559.25 | 536.93 | 643.93 | 518.28 | 446.18 | 429.06 |
Income Tax Expense | 106.58 | 103.79 | 122.4 | 96.99 | 116.65 | 85.34 |
Net Income | 452.67 | 433.13 | 521.53 | 421.3 | 329.53 | 343.72 |
Net Income to Common | 452.67 | 433.13 | 521.53 | 421.3 | 329.53 | 343.72 |
Net Income Growth | -13.99% | -16.95% | 23.79% | 27.85% | -4.13% | 24.08% |
Shares Outstanding (Basic) | 588 | 585 | 586 | 585 | 588 | 573 |
Shares Outstanding (Diluted) | 588 | 585 | 586 | 585 | 588 | 573 |
Shares Change (YoY) | 0.56% | -0.11% | 0.15% | -0.56% | 2.72% | -0.74% |
EPS (Basic) | 0.77 | 0.74 | 0.89 | 0.72 | 0.56 | 0.60 |
EPS (Diluted) | 0.77 | 0.74 | 0.89 | 0.72 | 0.56 | 0.60 |
EPS Growth | -14.48% | -16.85% | 23.61% | 28.57% | -6.67% | 25.00% |
Free Cash Flow | 584.84 | 621.18 | 506.16 | 472.85 | 466.4 | 266.15 |
Free Cash Flow Per Share | 0.99 | 1.06 | 0.86 | 0.81 | 0.79 | 0.47 |
Dividend Per Share | 0.500 | 0.500 | 0.600 | 0.600 | 0.800 | 0.900 |
Dividend Growth | -16.67% | -16.67% | - | -25.00% | -11.11% | 125.00% |
Gross Margin | 76.34% | 75.14% | 72.17% | 72.25% | 70.69% | 73.75% |
Operating Margin | 25.35% | 25.14% | 22.12% | 21.20% | 16.11% | 18.74% |
Profit Margin | 21.51% | 21.17% | 23.77% | 19.40% | 16.81% | 19.74% |
Free Cash Flow Margin | 27.79% | 30.36% | 23.07% | 21.77% | 23.80% | 15.29% |
EBITDA | 614.38 | 597.85 | 579.92 | 575.53 | 412.21 | 412.97 |
EBITDA Margin | 29.20% | 29.22% | 26.43% | 26.50% | 21.03% | 23.72% |
D&A For EBITDA | 80.88 | 83.62 | 94.59 | 115.12 | 96.55 | 86.6 |
EBIT | 533.5 | 514.23 | 485.33 | 460.41 | 315.65 | 326.37 |
EBIT Margin | 25.35% | 25.14% | 22.12% | 21.20% | 16.11% | 18.74% |
Effective Tax Rate | 19.06% | 19.33% | 19.01% | 18.71% | 26.15% | 19.89% |
Revenue as Reported | 2,104 | 2,046 | 2,194 | 2,172 | 1,960 | 1,741 |
Advertising Expenses | - | 470.71 | 530.36 | 514.72 | 361.86 | 378.93 |